Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 4 1

Status

Active not recruiting 4Terminated 1Recruiting 1No longer available 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × ceritinib × 90 days × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02393625 2026-04-02

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Novartis

Phase 1 Active not recruiting
57 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02584933 2026-04-02

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Active not recruiting
233 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡